These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15701343)

  • 21. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
    Tran TA; Kallakury BV; Sheehan CE; Ross JS
    Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of CD44s, CD44v5, CD44v6 and CD44v7-8 in betel quid chewing-associated oral premalignant lesions and squamous cell carcinomas in Taiwan.
    Kuo MY; Cheng SJ; Chen HM; Kok SH; Hahn LJ; Chiang CP
    J Oral Pathol Med; 1998 Oct; 27(9):428-33. PubMed ID: 9790096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.
    Afify AM; Ferguson AW; Davila RM; Werness BA
    Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):309-14. PubMed ID: 11759056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids.
    Afify A; Pang L; Howell L
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):446-50. PubMed ID: 18091389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
    Liu YJ; Yan PS; Li J; Jia JF
    World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD44V6 in gastric carcinoma: a marker of tumor progression.
    Xin Y; Grace A; Gallagher MM; Curran BT; Leader MB; Kay EW
    Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):138-42. PubMed ID: 11396631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis?
    Fasano M; Sabatini MT; Wieczorek R; Sidhu G; Goswami S; Jagirdar J
    Cancer; 1997 Jul; 80(1):34-41. PubMed ID: 9210706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma.
    Gansauge F; Gansauge S; Rau B; Scheiblich A; Poch B; Schoenberg MH; Beger HG
    Cancer; 1997 Nov; 80(9):1733-9. PubMed ID: 9351541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
    Ruibal A; Garrido-Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of combination assay of tumor markers in primary lung cancer patients].
    Hatakeyama S; Nagai A; Kioi S; Arakawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Aug; 28(8):1053-8. PubMed ID: 2173801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression tumor stem cell surface marker CD44 in gastric cancer and its significance].
    Xie JW; Huang CM; Zheng CH; Li P; Wang JB; Lin JX; Lu J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Nov; 16(11):1107-12. PubMed ID: 24277411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study.
    Ashida K; Terada T; Kitamura Y; Kaibara N
    Hepatology; 1998 Apr; 27(4):974-82. PubMed ID: 9537436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
    Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
    Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variant expression of CD44 in preneoplastic lesions of the lung.
    Wimmel A; Kogan E; Ramaswamy A; Schuermann M
    Cancer; 2001 Sep; 92(5):1231-6. PubMed ID: 11571737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
    Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
    Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features.
    Takigawa N; Segawa Y; Mandai K; Takata I; Fujimoto N
    Lung Cancer; 1997 Oct; 18(2):147-57. PubMed ID: 9316006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD44v6 expression in primary bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma.
    Ohori NP; Coppola D; Landreneau RJ
    Mod Pathol; 1996 May; 9(5):507-12. PubMed ID: 8733765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of human CD44v6 in non-small-cell lung cancer.
    Carbognani P; Spaggiari L; Romani A; Solli P; Corradi A; Cantoni AM; Petronini PG; Borghetti AF; Rusca M; Bobbio P
    Eur Surg Res; 1998; 30(6):403-8. PubMed ID: 9838232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.